Seeking Alpha

candigolden

candigolden
Send Message
View as an RSS Feed
View candigolden's Comments BY TICKER:
Latest  |  Highest rated
  • Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around zero after USA Today reports that the FDA has approved its Qnexa/Qysemia diet drug. However, no other news organizations appear to have reported the story, and it's not on the FDA website. Update: the linked-story in this MC seems to have been taken down. Vivus shares -0.6%.  [View news story]
    Hang in there - should be soon.
    Jul 17 02:10 PM | Likes Like |Link to Comment
  • Arena: Why You Should Wait For A Pullback [View article]
    thanks. all great points. except the colts part ...we are a bronco household. ;-)
    Jul 10 01:21 PM | Likes Like |Link to Comment
  • Arena: Why You Should Wait For A Pullback [View article]
    yes. it is a real question. i was just wondering thoughts as i am new to this industry. so much is going on with these two drugs. most research with medical professionals i have done sway towards VVUS. their sr. exec team selling makes me nervous. - and ARNA keeps climbing, just wondering if thoughts are it will dive if VVUS gets approved, or is there room for both????
    Jul 10 11:04 AM | Likes Like |Link to Comment
  • Arena: Why You Should Wait For A Pullback [View article]
    what if VVUS gets approved? do you think ARNA will still be on the northbound? would a takeover still be reality?
    Jul 10 10:25 AM | Likes Like |Link to Comment
  • Arena: Why You Should Wait For A Pullback [View article]
    You are incorrect. VVUS is July 17.
    Jul 10 09:49 AM | Likes Like |Link to Comment
  • Arena Pharmaceuticals (ARNA -3.6%) continues to give back some of the massive gains it enjoyed after the FDA approved its weight-loss drug Belviq. Orexigen, which surged on the news as well, is -4.7%. Vivus, though, (VVUS +1.5%) is still climbing ahead of an FDA decision on its Qnexa diet drug on July 17.  [View news story]
    yes i agree. VVUS will be in the $37-$40 range after approval.
    Jul 2 07:49 PM | Likes Like |Link to Comment
COMMENTS STATS
6 Comments
0 Likes